1 / 18

Enhanced Growth Factors with Medifuge-Silfradent: Impact on Blood Serum and Cell Expression

Explore the influence of Medifuge-Silfradent on growth factors in blood samples through histomorphometrical and quantitative analysis, revealing higher expressions of VEGF-A and TGF-β1. Enzymatic assays confirm decreased serum concentrations of these growth factors compared to control centrifuge treatments. Immunohistochemical analysis indicates a greater presence of CD34+ stem cells in the Red-Buffy Coat Interface following Medifuge-Silfradent treatment.

joemolina
Download Presentation

Enhanced Growth Factors with Medifuge-Silfradent: Impact on Blood Serum and Cell Expression

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CENTRIFUGES AND GROWTH FACTORS • Method: • 6 samples of blood; • Centrifuge (Silfradent protocol); • Histomorphometrical analysis of growth factors: TGF-1 e VEGF-A in Buffy Coat: • 1) Buffy Coat, 2) Red-buffy coat Interface e 3) Red Blood Cells 1, 2, 3; • Quantitative analysis of TGF-1 e VEGF-A in blood serum; • - Histomorphometrical analysis of CD34+ cells in Red-Buffy Coat Interface.

  2. MEDIFUGE- SILFRADENT CONTROL CENTRIFUGE SERUM BUFFY COAT RED BLOOD CELLS Buffy Coat Red- Buffy Coat Interface Red Blood 1 Red Blood 2 Red Blood 3

  3. * * P < 0,05 vs control centrifuge VEGF-A serum VEGF-A serum concentration is lower in the samples treated with Medifuge-Silfradent compared with control centrifuge.

  4. * * * * * *P < 0,05 vs control centrifuge VEGF-A expression The histomorphometrical analysis showed a greater expression of VEGF-A in the samples treated with Medifuge-Silfradent compared with control centrifuge.

  5. * * P < 0,05 vs control centrifuge VEGF-A Buffy Coat CONTROL Histomorphometrical analysis (IOD) of VEGF-A showed a greater expression of this growth factor in the Buffy Coat of samples treated with Medifuge-Silfradent compared with control centrifuge. MEDIFUGE

  6. * * P< 0,05 vs control centrifuge VEGF-A Red – Buffy Coat Interface CONTROL Histomorphometrical analysis (IOD) of VEGF-A showed a greater expression of this growth factor in the Buffy Coat of samples treated with Medifuge-Silfradent compared with control centrifuge. MEDIFUGE

  7. * * P< 0,05 vs control centrifuge VEGF-A Red Blood 1 CONTROL Histomorphometrical analysis (IOD) of VEGF-A showed a greater expression of this growth factor in the Red Blood 1 of samples treated with Medifuge-Silfradent compared with control centrifuge. MEDIFUGE

  8. * * P< 0,05 vs control centrifuge VEGF-A Red Blood 2 CONTROL Histomorphometrical analysis (IOD) of VEGF-A showed a greater expression of this growth factor in the Red Blood 2 of samples treated with Medifuge-Silfradent compared with control centrifuge. MEDIFUGE

  9. * * P< 0,05 vs control centrifuge VEGF-A Red Blood 3 CONTROL Histomorphometrical analysis (IOD) of VEGF-A showed a greater expression of this growth factor in the Red Blood 3 of samples treated with Medifuge-Silfradent with control centrifuge. MEDIFUGE

  10. * * P< 0,05 vs control centrifuge TGF-β1 Serum TGF-β1serum concentration is lower in samples treated with Medifuge-Silfradent compared with control centrifuge.

  11. TGF-β1 expression * * * * * * P < 0,05 vs control centrifuge The histomorphometrical analysis showed a greater expression of TGF-β1in samples treated with Medifuge-Silfradent compared with control centrifuge.

  12. * * P < 0,05 vs control centrifuge TGF-β1Buffy Coat CONTROL Histomorphometrical analysis (IOD) of TGF-β1 showed a greater expression of this growth factor in the Buffy Coat of samples treated with Medifuge-Silfradent compared with control centrifuge. MEDIFUGE

  13. * * P < 0,05 vs control centrifuge TGF-β1 Red – Buffy Coat Interface CONTROL Histomorphometrical analysis (IOD) of TGF-β1 showed a greater expression of this growth factor in the Red-Buffy Coat of samples treated with Medifuge-Silfradent compared with control centrifuge. MEDIFUGE

  14. * * P < 0,05 vs control centrifuge TGF-β1 Red Blood 1 CONTROL Histomorphometrical analysis (IOD) of TGF-β1 showed a greater expression of this growth factor in the Red Blood 1 of samples treated with Medifuge-Silfradent compared with control centrifuge. MEDIFUGE

  15. * * P < 0,05 vs control centrifuge TGF-β1 Red Blood 2 CONTROL Histomorphometrical analysis (IOD) of TGF-β1 showed a greater expression of this growth factor in the Red Blood 2 of samples treated with Medifuge-Silfradent compared with control centrifuge. MEDIFUGE

  16. * * P < 0,05 vs control centrifuge TGF-β1 Red Blood 3 CONTROL Histomorphometrical analysis (IOD) of TGF-β1 showed a greater expression of this growth factor in the Red Blood 3 of samples treated with Medifuge-Silfradent compared with control centrifuge. MEDIFUGE

  17. VEGF-A and TGF-β1 results • The histomorphometric analysis (IOD) of blood growth factors TGF-1 and VEGF-A showed a greater expression of these growth factors in the samples treated with Medifuge-Silfradent compared with control centrifuge. • Enzymatic analysis of VEGF-A e TGF-1 has confirmed our previous results showing a significant difference of both growth factors serum concentration: in particular, we found a lower serum concentration of both growth factors in the samples treated with Medifuge-Silfradent compared with control centrifuge. Bar 10 μm

  18. CD 34 Stem cells Red- Buffy Coat Interface CONTROL MEDIFUGE • - The immunohistochemical analysis of the Red-Buffy Coat Interface showed a greater number of white cells in samples treated with Medifuge-Silfradent centrifuge with control centrifuge, as suggest by our previous analysis. • - The immunohistochemical analysis of cells CD34+ expressed in the Red-Buffy Coat Interface showed a number of cells CD34+ four time greater in the samples trated with Medifuge-Silfradent centrifuge compared with control centrifuge.

More Related